Replication-competent herpes simplex virus retargeted to HER2 as therapy for high-grade glioma

Molecular Therapy

Volumn 20, Issue 5, 2012, Pages 994-1001

  Gambini, Eleonora ^a   Reisoli, Elisa ^b   Appolloni, Irene ^a   Gatta, Valentina ^c   Campadelli Fiume, Gabriella ^c   Menotti, Laura ^c   Malatesta, Paolo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ONCOLYTIC HERPES VIRUS; R LM113; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CHEMOTHERAPY; CANCER SURVIVAL; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; GENE OVEREXPRESSION; GLIOBLASTOMA; HERPES SIMPLEX VIRUS; IN VIVO STUDY; MOUSE; NONHUMAN; ONCOLYTIC VIROTHERAPY; PROTEIN EXPRESSION; PROTEIN TARGETING; SURVIVAL TIME; TARGET CELL; TUMOR GROWTH; VIRUS REPLICATION;

MUS; SIMPLEXVIRUS;

EID: 84860542782     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2012.22     Document Type: Article

References (43)

1. CBTRUS (ed.). (2011) CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States, 2004-2007. Central Brain Tumor Registry of the United States: Hinsdale, IL.
2. Stupp, R, Mason, WP, van den Bent, MJ, Weller, M, Fisher, B, Taphoorn, MJ et al.; European Organisation for Research and Treatment of Cancer Brain Tumor and Radiotherapy Groups; National Cancer Institute of Canada Clinical Trials Group. (2005). Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352: 987-996. (Pubitemid 40349501)
3. Campadelli-Fiume, G, De Giovanni, C, Gatta, V, Nanni, P, Lollini, PL and Menotti, L (2011). Rethinking herpes simplex virus: the way to oncolytic agents. Rev Med Virol 21: 213-226.
4. Menotti, L, Campadelli-Fiume, G, Nanni, P, Lollini, PL and De Giovanni, C (2011). The molecular basis of herpesviruses as oncolytic agents. Curr Pharm Biotechnol (epub ahead of print).
5. Cattaneo, R, Miest, T, Shashkova, EV and Barry, MA (2008). Reprogrammed viruses as cancer therapeutics: targeted, armed and shielded. Nat Rev Microbiol 6: 529-540. (Pubitemid 351850977)
6. Zhou, G and Roizman, B (2006). Construction and properties of a herpes simplex virus 1 designed to enter cells solely via the IL-13?2 receptor. Proc Natl Acad Sci USA 103: 5508-5513.
7. Zhou, G, Ye, GJ, Debinski, W and Roizman, B (2002). Engineered herpes simplex virus 1 is dependent on IL13R2 receptor for cell entry and independent of glycoprotein D receptor interaction. Proc Natl Acad Sci USA 99: 15124-15129. (Pubitemid 35334620)
8. Kamiyama, H, Zhou, G and Roizman, B (2006). Herpes simplex virus 1 recombinant virions exhibiting the amino terminal fragment of urokinase-type plasminogen activator can enter cells via the cognate receptor. Gene Ther 13: 621-629.
9. Menotti, L, Cerretani, A, Hengel, H and Campadelli-Fiume, G (2008). Construction of a fully retargeted herpes simplex virus 1 recombinant capable of entering cells solely via human epidermal growth factor receptor 2. J Virol 82: 10153-10161.
10. Menotti, L, Nicoletti, G, Gatta, V, Croci, S, Landuzzi, L, De Giovanni, C et al. (2009). Inhibition of human tumor growth in mice by an oncolytic herpes simplex virus designed to target solely HER-2-positive cells. Proc Natl Acad Sci USA 106: 9039-9044.
11. Menotti, L, Cerretani, A and Campadelli-Fiume, G (2006). A herpes simplex virus recombinant that exhibits a single-chain antibody to HER2/neu enters cells through the mammary tumor receptor, independently of the gD receptors. J Virol 80: 5531-5539.
12. Duhem-Tonnelle, V, Bièche, I, Vacher, S, Loyens, A, Maurage, CA, Collier, F et al. (2010). Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. J Neuropathol Exp Neurol 69: 606-622.
13. Mineo, JF, Bordron, A, Baroncini, M, Maurage, CA, Ramirez, C, Siminski, RM et al. (2007). Low HER2-expressing glioblastomas are more often secondary to anaplastic transformation of low-grade glioma. J Neurooncol 85: 281-287. (Pubitemid 350142517)
14. Nabika, S, Kiya, K, Satoh, H, Mizoue, T, Kondo, H, Katagiri, M et al. (2010). Prognostic significance of expression patterns of EGFR family, p21 and p27 in high-grade astrocytoma. Hiroshima J Med Sci 59: 65-70.
15. Hiesiger, EM, Hayes, RL, Pierz, DM and Budzilovich, GN (1993). Prognostic relevance of epidermal growth factor receptor (EGF-R) and c-neu/erbB2 expression in glioblastomas (GBMs). J Neurooncol 16: 93-104. (Pubitemid 23304716)
16. Gulati, S, Ytterhus, B, Granli, US, Gulati, M, Lydersen, S and Torp, SH (2010). Overexpression of c-erbB2 is a negative prognostic factor in anaplastic astrocytomas. Diagn Pathol 5: 18.
17. Ahmed, N, Salsman, VS, Kew, Y, Shaffer, D, Powell, S, Zhang, YJ et al. (2010). HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res 16: 474-485.
18. Press, MF, Cordon-Cardo, C and Slamon, DJ (1990). Expression of the HER-2/neu proto-oncogene in normal human adult and fetal tissues. Oncogene 5: 953-962.
19. Appolloni, I, Calzolari, F, Tutucci, E, Caviglia, S, Terrile, M, Corte, G et al. (2009). PDGF-B induces a homogeneous class of oligodendrogliomas from embryonic neural progenitors. Int J Cancer 124: 2251-2259.
20. Calzolari, F, Appolloni, I, Tutucci, E, Caviglia, S, Terrile, M, Corte, G et al. (2008). Tumor progression and oncogene addiction in a PDGF-B-induced model of gliomagenesis. Neoplasia 10: 1373-82, following 1382.
21. Terrile, M, Appolloni, I, Calzolari, F, Perris, R, Tutucci, E and Malatesta, P (2010). PDGF-B-driven gliomagenesis can occur in the absence of the proteoglycan NG2. BMC Cancer 10: 550.
22. Dai, C, Celestino, JC, Okada, Y, Louis, DN, Fuller, GN and Holland, EC (2001). PDGF autocrine stimulation dedifferentiates cultured astrocytes and induces oligodendrogliomas and oligoastrocytomas from neural progenitors and astrocytes in vivo. Genes Dev 15: 1913-1925. (Pubitemid 32738621)
23. Verhaak, RG, Hoadley, KA, Purdom, E, Wang, V, Qi, Y, Wilkerson, MD et al.; Cancer Genome Atlas Research Network. (2010). Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell 17: 98-110.
24. Valyi-Nagy, T, Fareed, MU, O'Keefe, JS, Gesser, RM, MacLean, AR, Brown, SM et al. (1994). The herpes simplex virus type 1 strain 17+ 34.5 deletion mutant 1716 is avirulent in SCID mice. J Gen Virol 75 (Pt 8): 2059-2063. (Pubitemid 24243088)
25. Harrow, S, Papanastassiou, V, Harland, J, Mabbs, R, Petty, R, Fraser, M et al. (2004). HSV1716 injection into the brain adjacent to tumour following surgical resection of high-grade glioma: safety data and long-term survival. Gene Ther 11: 1648-1658. (Pubitemid 39530101)
26. Markert, JM, Liechty, PG, Wang, W, Gaston, S, Braz, E, Karrasch, M et al. (2009). Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol Ther 17: 199-207.
27. Markert, JM, Gillespie, GY, Weichselbaum, RR, Roizman, B and Whitley, RJ (2000). Genetically engineered HSV in the treatment of glioma: a review. Rev Med Virol 10: 17-30. (Pubitemid 30103131)
28. Smith, KD, Shao, MY, Posner, MC and Weichselbaum, RR (2007). Tumor genotype determines susceptibility to oncolytic herpes simplex virus mutants: strategies for clinical application. Future Oncol 3: 545-556. (Pubitemid 47602771)
29. Liu, C, Hasegawa, K, Russell, SJ, Sadelain, M and Peng, KW (2009). Prostate-specific membrane antigen retargeted measles virotherapy for the treatment of prostate cancer. Prostate 69: 1128-1141.
30. Nakamura, T, Peng, KW, Harvey, M, Greiner, S, Lorimer, IA, James, CD et al. (2005). Rescue and propagation of fully retargeted oncolytic measles viruses. Nat Biotechnol 23: 209-214. (Pubitemid 40255331)
31. Miest, TS, Yaiw, KC, Frenzke, M, Lampe, J, Hudacek, AW, Springfeld, C et al. (2011). Envelope-chimeric entry-targeted measles virus escapes neutralization and achieves oncolysis. Mol Ther 19: 1813-1820.
32. Gao, Y, Whitaker-Dowling, P, Griffin, JA, Barmada, MA and Bergman, I (2009). Recombinant vesicular stomatitis virus targeted to Her2/neu combined with anti-CTLA4 antibody eliminates implanted mammary tumors. Cancer Gene Ther 16: 44-52.
33. Paraskevakou, G, Allen, C, Nakamura, T, Zollman, P, James, CD, Peng, KW et al. (2007). Epidermal growth factor receptor (EGFR)-retargeted measles virus strains effectively target EGFR-or EGFRvIII expressing gliomas. Mol Ther 15: 677-686. (Pubitemid 46431987)
34. Allen, C, Vongpunsawad, S, Nakamura, T, James, CD, Schroeder, M, Cattaneo, R et al. (2006). Retargeted oncolytic measles strains entering via the EGFRvIII receptor maintain significant antitumor activity against gliomas with increased tumor specificity. Cancer Res 66: 11840-11850. (Pubitemid 46094196)
35. Bossow, S, Grossardt, C, Temme, A, Leber, MF, Sawall, S, Rieber, EP et al. (2011). Armed and targeted measles virus for chemovirotherapy of pancreatic cancer. Cancer Gene Ther 18: 598-608.
36. Varghese, S, Rabkin, SD, Nielsen, PG, Wang, W and Martuza, RL (2006). Systemic oncolytic herpes virus therapy of poorly immunogenic prostate cancer metastatic to lung. Clin Cancer Res 12: 2919-2927.
37. Parker, JN, Gillespie, GY, Love, CE, Randall, S, Whitley, RJ and Markert, JM (2000). Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proc Natl Acad Sci USA 97: 2208-2213. (Pubitemid 30134047)
38. Hu, JC, Coffin, RS, Davis, CJ, Graham, NJ, Groves, N, Guest, PJ et al. (2006). A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 12: 6737-6747. (Pubitemid 44876843)
39. Uchida, H, Chan, J, Goins, WF, Grandi, P, Kumagai, I, Cohen, JB et al. (2010). A double mutation in glycoprotein gB compensates for ineffective gD-dependent initiation of herpes simplex virus type 1 infection. J Virol 84: 12200-12209.
40. Melisko, ME, Glantz, M and Rugo, HS (2009). New challenges and opportunities in the management of brain metastases in patients with ErbB2-positive metastatic breast cancer. Nat Clin Pract Oncol 6: 25-33.
41. Nahta, R, Yu, D, Hung, MC, Hortobagyi, GN and Esteva, FJ (2006). Mechanisms of disease: understanding resistance to HER2-targeted therapy in human breast cancer. Nat Clin Pract Oncol 3: 269-280. (Pubitemid 43731112)
42. Casalini, P, Botta, L and Menard, S (2001). Role of p53 in HER2-induced proliferation or apoptosis. J Biol Chem 276: 12449-12453.
43. Takahashi, T, Nowakowski, RS and Caviness, VS Jr (1993). Cell cycle parameters and patterns of nuclear movement in the neocortical proliferative zone of the fetal mouse. J Neurosci 13: 820-833. (Pubitemid 23045162)